KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biogen (BIIB) Long-Term Debt Repayments (2017 - 2025)

Biogen has reported Long-Term Debt Repayments over the past 10 years, most recently at $1.8 billion for Q2 2025.

  • Quarterly results put Long-Term Debt Repayments at $1.8 billion for Q2 2025, up 600.0% from a year ago — trailing twelve months through Dec 2025 was $1.8 billion (up 169.23% YoY), and the annual figure for FY2025 was $1.8 billion, up 169.23%.
  • Long-Term Debt Repayments for Q2 2025 was $1.8 billion at Biogen, up from $250.0 million in the prior quarter.
  • Over the last five years, Long-Term Debt Repayments for BIIB hit a ceiling of $1.8 billion in Q2 2025 and a floor of -$1.0 billion in Q4 2022.
  • Median Long-Term Debt Repayments over the past 5 years was $169.3 million (2021), compared with a mean of $294.3 million.
  • Peak annual rise in Long-Term Debt Repayments hit 7162.32% in 2022, while the deepest fall reached 489.53% in 2022.
  • Biogen's Long-Term Debt Repayments stood at -$170.0 million in 2021, then plummeted by 489.53% to -$1.0 billion in 2022, then soared by 164.86% to $650.0 million in 2023, then crashed by 61.54% to $250.0 million in 2024, then skyrocketed by 600.0% to $1.8 billion in 2025.
  • The last three reported values for Long-Term Debt Repayments were $1.8 billion (Q2 2025), $250.0 million (Q2 2024), and $400.0 million (Q1 2024) per Business Quant data.